share_log

Phio Pharmaceuticals | 8-K: Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals | 8-K: Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals | 8-K：Phio 製藥公佈2024年第二季度財務業績並提供業務最新情況
美股SEC公告 ·  2024/08/14 17:07

Moomoo AI 已提取核心訊息

Phio Pharmaceuticals reported Q2 2024 financial results with cash position of $4.7 million as of June 30, 2024, down from $8.5 million at year-end 2023. The company secured additional $2.6 million through warrant exercises in July 2024. Q2 net loss decreased to $1.8 million from $2.5 million YoY, with R&D expenses down 37% to $0.9 million.The Phase 1b clinical trial for lead candidate PH-762 received positive safety recommendation, showing no dose-limiting toxicities or clinically relevant adverse events in the initial cohort. The trial is now enrolling for the second cohort with five clinical sites, including the newly added University of Pittsburgh Medical Center.Recent corporate updates include the appointment of Robert M. Infarinato as CFO, completion of a 1-for-9 reverse stock split, regaining Nasdaq compliance, and entering an exploratory collaboration with a global skin care company. The company also strengthened its patent portfolio with a new South Korean patent for INTASYL compounds targeting aging skin disorders.
Phio Pharmaceuticals reported Q2 2024 financial results with cash position of $4.7 million as of June 30, 2024, down from $8.5 million at year-end 2023. The company secured additional $2.6 million through warrant exercises in July 2024. Q2 net loss decreased to $1.8 million from $2.5 million YoY, with R&D expenses down 37% to $0.9 million.The Phase 1b clinical trial for lead candidate PH-762 received positive safety recommendation, showing no dose-limiting toxicities or clinically relevant adverse events in the initial cohort. The trial is now enrolling for the second cohort with five clinical sites, including the newly added University of Pittsburgh Medical Center.Recent corporate updates include the appointment of Robert M. Infarinato as CFO, completion of a 1-for-9 reverse stock split, regaining Nasdaq compliance, and entering an exploratory collaboration with a global skin care company. The company also strengthened its patent portfolio with a new South Korean patent for INTASYL compounds targeting aging skin disorders.
Phio Pharmaceuticals於2024年第二季度公佈財務結果，截至2024年6月30日現金餘額爲470萬美元，低於2023年底的850萬美元。該公司在2024年7月通過認股權證行使額外獲得260萬美元。第二季度淨虧損同比減少至180萬美元，較去年的250萬美元減少，研發費用下降37%至90萬美元。用於主導候選藥物PH-762的10億期臨牀試驗獲得了積極的安全性推薦，在初始隊列中未出現劑量限制性毒性或臨牀相關的不良事件。該試驗現正招募第二隊列，參與的臨牀地點包括新增加的匹茲堡大學醫療中心。近期公司更新包括任命Robert m. Infarinato爲財務長，完成1比9的反向拆股，重新獲得納斯達克合規，並與一家全球護膚公司達成探索性合作。該公司還通過針對衰老肌膚疾病的新韓國專利，增強了其專利組合。
Phio Pharmaceuticals於2024年第二季度公佈財務結果，截至2024年6月30日現金餘額爲470萬美元，低於2023年底的850萬美元。該公司在2024年7月通過認股權證行使額外獲得260萬美元。第二季度淨虧損同比減少至180萬美元，較去年的250萬美元減少，研發費用下降37%至90萬美元。用於主導候選藥物PH-762的10億期臨牀試驗獲得了積極的安全性推薦，在初始隊列中未出現劑量限制性毒性或臨牀相關的不良事件。該試驗現正招募第二隊列，參與的臨牀地點包括新增加的匹茲堡大學醫療中心。近期公司更新包括任命Robert m. Infarinato爲財務長，完成1比9的反向拆股，重新獲得納斯達克合規，並與一家全球護膚公司達成探索性合作。該公司還通過針對衰老肌膚疾病的新韓國專利，增強了其專利組合。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Corcept醫療
    CORT
    -- 104.750
    bluebird bio
    BLUE
    -- 5.165
    ABVC BioPharma
    ABVC
    -- 1.0100
    NLS Pharmaceutics
    NLSP
    -- 1.4758
    Apollomics
    APLM
    -- 8.415
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日